Post by Biomed Industries Inc

Biomed Industries, Inc. Announces Phase 2 Success of NA-931: an Oral Quadruple Receptor Agonist for Obesity at EASD 2025 Dr. Lloyd L. Tran, the company’s Chief Executive Officer, presented results from its Phase 2 clinical trial of NA-931, a first-in-class oral quadruple receptor agonist for the treatment of obesity, at the EASD 2025 (European Association for the Study of Diabetes). The Phase 2 trial confirmed the robust efficacy and favorable safety profile seen in Phase 1. NA-931 achieved weight loss outcomes on par with leading approved and late-stage injectable therapies, while showing significantly fewer and milder side effects. Read more at: https://lnkd.in/giuTdj9b #Bioglutide